These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21306774)

  • 1. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery.
    Yao HJ; Ju RJ; Wang XX; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
    Biomaterials; 2011 Apr; 32(12):3285-302. PubMed ID: 21306774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
    Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
    Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
    Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
    Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration.
    Dian LH; Hu YJ; Lin JY; Zhang JY; Yan Y; Cui YN; Su ZB; Lu WL
    Int J Nanomedicine; 2018; 13():719-731. PubMed ID: 29440897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
    Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.
    Zhang Y; Li RJ; Ying X; Tian W; Yao HJ; Men Y; Yu Y; Zhang L; Ju RJ; Wang XX; Zhou J; Chen JX; Li N; Lu WL
    Mol Pharm; 2011 Feb; 8(1):162-75. PubMed ID: 21062083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
    Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
    Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.
    Koziara JM; Whisman TR; Tseng MT; Mumper RJ
    J Control Release; 2006 May; 112(3):312-9. PubMed ID: 16626835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis.
    Wang H; Zhang F; Wen H; Shi W; Huang Q; Huang Y; Xie J; Li P; Chen J; Qin L; Zhou Y
    J Nanobiotechnology; 2020 Jan; 18(1):8. PubMed ID: 31918714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.
    Zhang Y; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2012 Jan; 33(2):679-91. PubMed ID: 22019123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
    Lv PP; Wei W; Yue H; Yang TY; Wang LY; Ma GH
    Biomacromolecules; 2011 Dec; 12(12):4230-9. PubMed ID: 22044456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TPGS/Phospholipids Mixed Micelles for Delivery of Icariside II to Multidrug-Resistant Breast Cancer.
    Song J; Huang H; Xia Z; Wei Y; Yao N; Zhang L; Yan H; Jia X; Zhang Z
    Integr Cancer Ther; 2016 Sep; 15(3):390-9. PubMed ID: 26293804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
    Baek JS; Cho CW
    J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
    Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
    Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
    Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
    Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.
    Xiao H; Song H; Yang Q; Cai H; Qi R; Yan L; Liu S; Zheng Y; Huang Y; Liu T; Jing X
    Biomaterials; 2012 Sep; 33(27):6507-19. PubMed ID: 22727463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.